JP2018500337A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018500337A5 JP2018500337A5 JP2017532675A JP2017532675A JP2018500337A5 JP 2018500337 A5 JP2018500337 A5 JP 2018500337A5 JP 2017532675 A JP2017532675 A JP 2017532675A JP 2017532675 A JP2017532675 A JP 2017532675A JP 2018500337 A5 JP2018500337 A5 JP 2018500337A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequences
- acid sequence
- cell
- car
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 42
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 24
- 210000004027 cell Anatomy 0.000 claims description 20
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims description 16
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims description 16
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims description 12
- 108700012439 CA9 Proteins 0.000 claims description 6
- 230000004068 intracellular signaling Effects 0.000 claims description 6
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 230000000139 costimulatory effect Effects 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 108020003175 receptors Proteins 0.000 claims description 4
- 102000005962 receptors Human genes 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 208000030808 Clear cell renal carcinoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- -1 ICOS Proteins 0.000 claims description 2
- 108010002350 Interleukin-2 Proteins 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 206010073251 clear cell renal cell carcinoma Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 210000000822 natural killer cell Anatomy 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 6
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 201000011330 nonpapillary renal cell carcinoma Diseases 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 14
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 description 8
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462094596P | 2014-12-19 | 2014-12-19 | |
| US62/094,596 | 2014-12-19 | ||
| PCT/US2015/067178 WO2016100980A1 (en) | 2014-12-19 | 2015-12-21 | Carbonic anhydrase ix specific chimeric antigen receptors and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018500337A JP2018500337A (ja) | 2018-01-11 |
| JP2018500337A5 true JP2018500337A5 (OSRAM) | 2019-02-07 |
Family
ID=55273519
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017532675A Pending JP2018500337A (ja) | 2014-12-19 | 2015-12-21 | 炭酸脱水酵素ｉｘ特異的キメラ抗原受容体およびその使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US10870705B2 (OSRAM) |
| EP (1) | EP3233901A1 (OSRAM) |
| JP (1) | JP2018500337A (OSRAM) |
| KR (1) | KR20170093248A (OSRAM) |
| CN (1) | CN108064251A (OSRAM) |
| AU (1) | AU2015364240A1 (OSRAM) |
| BR (1) | BR112017013177A2 (OSRAM) |
| CA (1) | CA2968555A1 (OSRAM) |
| IL (1) | IL252366A0 (OSRAM) |
| RU (1) | RU2017125735A (OSRAM) |
| WO (1) | WO2016100980A1 (OSRAM) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20170090506A (ko) * | 2014-12-19 | 2017-08-07 | 다나-파버 캔서 인스티튜트 인크. | 키메라 항원 수용체 및 이의 사용 방법 |
| CA3038150A1 (en) * | 2016-12-22 | 2018-06-28 | Windmil Therapeutics, Inc. | Compositions and methods for modulating the immune system |
| WO2019149279A1 (zh) | 2018-02-02 | 2019-08-08 | 科济生物医药（上海）有限公司 | 细胞免疫治疗的组合 |
| US20220047634A1 (en) * | 2018-11-30 | 2022-02-17 | Dana-Farber Cancer Institute, Inc. | Chimeric antigen receptor factories and methods of use thereof |
| CN109705225B (zh) * | 2019-01-21 | 2022-02-22 | 徐州医科大学 | 一种抗人caix抗原的嵌合抗原受体及其应用 |
| TWI869344B (zh) * | 2019-05-06 | 2025-01-11 | 納維再生科技股份有限公司 | 抗-碳酸酐酶ix抗體 |
| EP3966253A4 (en) * | 2019-05-06 | 2023-02-22 | Navi Bio-Therapeutics, Inc. | ANTI-CARBONIC ANHYDRASE IX ANTIBODIES |
| CN112552408B (zh) * | 2019-09-10 | 2022-09-20 | 普米斯生物技术(珠海)有限公司 | 靶向caix抗原的纳米抗体及其应用 |
| US12331131B2 (en) * | 2019-09-20 | 2025-06-17 | Navi Bio-Therapeutics, Inc. | Personalized cancer immunotherapy |
| CN113045665B (zh) * | 2021-03-22 | 2022-05-13 | 徐州医科大学 | 一种hvem共刺激信号驱动的caix-car-t细胞及其制备方法和应用 |
| US12486304B2 (en) * | 2022-02-11 | 2025-12-02 | C-Biomex Co., Ltd. | Peptide ligand targeting carbonic anhydrase IX, peptide construct comprising same, and uses thereof |
| CN116102662A (zh) * | 2022-10-10 | 2023-05-12 | 武汉波睿达生物科技有限公司 | 一种靶向ca9的融合嵌合抗原受体、重组表达载体及其应用 |
| TW202442689A (zh) | 2023-03-03 | 2024-11-01 | 美商亞森諾生物科學公司 | 靶向ｐｓｍａ及ｃａ９之系統 |
| WO2025064539A1 (en) | 2023-09-19 | 2025-03-27 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Herv-e antibodies and methods of their use |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| CN101031255A (zh) | 2004-06-30 | 2007-09-05 | 科迪斯公司 | 具有非对称构件的管腔内医疗器械以及最优化方法 |
| EP1979379B1 (en) | 2005-12-02 | 2013-09-18 | Dana-Farber Cancer Institute | Carbonic anhydrase ix (g250) antibodies and methods of use thereof |
| DE102008030837A1 (de) | 2008-06-30 | 2010-01-14 | Siemens Aktiengesellschaft | Elektrochrome Formulierung, Herstellungsverfahren dazu und elektrochromes organisches Bauelement |
| FR2933058B1 (fr) | 2008-06-30 | 2010-08-27 | Zf Systemes De Direction Nacam Sas | Dispositif d'assistance au verrouillage d'une colonne de direction |
| US20150320799A1 (en) * | 2012-12-20 | 2015-11-12 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| DK2981607T3 (da) * | 2013-04-03 | 2020-11-16 | Memorial Sloan Kettering Cancer Center | Effektiv generering af tumormålrettede t-celler afledt af pluripotente stamceller |
| FR3023477B1 (fr) | 2014-07-10 | 2017-11-24 | Oreal | Utilisation cosmetique de l'acide spiculisporique comme actif deodorant |
-
2015
- 2015-12-21 BR BR112017013177A patent/BR112017013177A2/pt not_active Application Discontinuation
- 2015-12-21 CN CN201580068869.2A patent/CN108064251A/zh active Pending
- 2015-12-21 EP EP15831023.5A patent/EP3233901A1/en not_active Withdrawn
- 2015-12-21 KR KR1020177020099A patent/KR20170093248A/ko not_active Ceased
- 2015-12-21 US US15/537,780 patent/US10870705B2/en active Active
- 2015-12-21 AU AU2015364240A patent/AU2015364240A1/en not_active Abandoned
- 2015-12-21 RU RU2017125735A patent/RU2017125735A/ru not_active Application Discontinuation
- 2015-12-21 WO PCT/US2015/067178 patent/WO2016100980A1/en not_active Ceased
- 2015-12-21 CA CA2968555A patent/CA2968555A1/en not_active Abandoned
- 2015-12-21 JP JP2017532675A patent/JP2018500337A/ja active Pending
-
2017
- 2017-05-18 IL IL252366A patent/IL252366A0/en unknown
-
2020
- 2020-12-21 US US17/129,369 patent/US12024567B2/en active Active
-
2024
- 2024-05-21 US US18/670,431 patent/US20250011462A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018500337A5 (OSRAM) | ||
| RU2017125735A (ru) | Химерные антигенные рецепторы против карбоангидразы ix и способы их применения | |
| JP2019532625A5 (OSRAM) | ||
| JP2019510733A5 (OSRAM) | ||
| JP2018504094A5 (OSRAM) | ||
| FI3703750T3 (fi) | B-solujen maturaatioantigeenille spesifisiä kimeerisiä antigeenireseptoreita ja koodaavia polynukleotideja | |
| JP2016508725A5 (OSRAM) | ||
| RU2018111462A (ru) | Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток | |
| US20190151365A1 (en) | Combination therapies of chimeric antigen receptors and pd-1 inhibitors | |
| JP2018506981A5 (OSRAM) | ||
| JP2020530989A5 (OSRAM) | ||
| FI4063397T3 (fi) | Yksidomeenivasta-aineisiin perustuvia antigeenireseptoreita ja menetelmiä niiden käyttämiseksi | |
| IL268620B2 (en) | Antibodies against LAG3 pharmaceutical formulations containing them, and their uses for cancer treatment | |
| JP2017513478A5 (OSRAM) | ||
| JP2018508215A5 (OSRAM) | ||
| JP2017500869A5 (OSRAM) | ||
| JP2017508466A5 (OSRAM) | ||
| RU2018107802A (ru) | Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин | |
| JP2015527070A5 (OSRAM) | ||
| RU2018135247A (ru) | БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА К CD25 И Fc ГАММА-РЕЦЕПТОРУ ДЛЯ ЭЛИМИНАЦИИ ОПУХОЛЕСПЕЦИФИЧЕСКИХ КЛЕТОК | |
| RU2017137251A (ru) | Комбинация антител cd30xcd16 для терапии с антагонистом pd-1 | |
| JP2018532407A5 (OSRAM) | ||
| JP2018518939A5 (OSRAM) | ||
| JP2015509717A5 (OSRAM) | ||
| TW201904997A (zh) | 引導及導航控制蛋白質以及彼之製造及使用方法 |